ACT Brief: De-Identified RWE Gains Ground, HHS Funding Stabilizes Research, and U.S. Finalizes WHO Exit episode artwork

EPISODE · Jan 23, 2026 · 2 MIN

ACT Brief: De-Identified RWE Gains Ground, HHS Funding Stabilizes Research, and U.S. Finalizes WHO Exit

from Applied Clinical Trials · host Applied Clinical Trials

In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical development, why a new bipartisan funding package could stabilize federal research agencies, and how the US withdrawal from the World Health Organization reshapes global health coordination.

Episode metadata supplied by the publisher feed · Published Jan 23, 2026

Embed this episode

Ready to play

ACT Brief: De-Identified RWE Gains Ground, HHS Funding Stabilizes Research, and U.S. Finalizes WHO Exit

0:00 2:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Applied Clinical Trials?

This episode is 2 minutes long.

When was this Applied Clinical Trials episode published?

This episode was published on January 23, 2026.

Can I download this Applied Clinical Trials episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!